The content on this site is intended for healthcare professionals only
Dr Nghiem speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the latest finding in the field of Merkel cell carcinoma. He highlights that there have been major developments in the settings of first-line treatment, treatment after chemotherapy and the neoadjuvant setting.
He goes on to discuss the importance and benefit of immune therapy over chemotherapy in this setting.
Innovating cancer care access for low and middle-income countries
Addressing cancer control challenges in Africa
Multiple myeloma In Rwanda: The need for further research
Synthetic biology and precision medicine in blood and gynaecological cancers
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 15-21, 2023
The Southeast Asian Breast Cancer Symposium; background, aims and successes
